Biogen Inc (BIIB)
224.93
+4.86
(+2.21%)
USD |
NASDAQ |
May 31, 16:00
224.94
+0.01
(+0.00%)
After-Hours: 20:00
Biogen Price to Book Value: 2.153 for May 31, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 2.153 |
| May 30, 2024 | 2.106 |
| May 29, 2024 | 2.052 |
| May 28, 2024 | 2.093 |
| May 24, 2024 | 2.085 |
| May 23, 2024 | 2.087 |
| May 22, 2024 | 2.155 |
| May 21, 2024 | 2.179 |
| May 20, 2024 | 2.216 |
| May 17, 2024 | 2.207 |
| May 16, 2024 | 2.202 |
| May 15, 2024 | 2.252 |
| May 14, 2024 | 2.171 |
| May 13, 2024 | 2.157 |
| May 10, 2024 | 2.120 |
| May 09, 2024 | 2.132 |
| May 08, 2024 | 2.103 |
| May 07, 2024 | 2.095 |
| May 06, 2024 | 2.119 |
| May 03, 2024 | 2.082 |
| May 02, 2024 | 2.043 |
| May 01, 2024 | 2.068 |
| April 30, 2024 | 2.056 |
| April 29, 2024 | 2.062 |
| April 26, 2024 | 1.999 |
| Date | Value |
|---|---|
| April 25, 2024 | 1.938 |
| April 24, 2024 | 1.933 |
| April 23, 2024 | 1.849 |
| April 22, 2024 | 1.858 |
| April 19, 2024 | 1.850 |
| April 18, 2024 | 1.813 |
| April 17, 2024 | 1.829 |
| April 16, 2024 | 1.858 |
| April 15, 2024 | 1.873 |
| April 12, 2024 | 1.886 |
| April 11, 2024 | 1.939 |
| April 10, 2024 | 1.918 |
| April 09, 2024 | 1.966 |
| April 08, 2024 | 1.951 |
| April 05, 2024 | 1.940 |
| April 04, 2024 | 1.954 |
| April 03, 2024 | 1.964 |
| April 02, 2024 | 1.976 |
| April 01, 2024 | 2.045 |
| March 31, 2024 | |
| March 28, 2024 | 2.118 |
| March 27, 2024 | 2.125 |
| March 26, 2024 | 2.082 |
| March 25, 2024 | 2.128 |
| March 22, 2024 | 2.142 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
1.813
Minimum
Apr 18 2024
5.845
Maximum
Jun 10 2021
3.302
Average
3.276
Median
Dec 10 2021
Price to Book Value Benchmarks
| Ionis Pharmaceuticals Inc | 18.51 |
| Eli Lilly and Co | 60.85 |
| Bristol-Myers Squibb Co | 5.051 |
| Regeneron Pharmaceuticals Inc | 4.003 |
| Sage Therapeutics Inc | 0.9465 |
Price to Book Value Related Metrics
| PE Ratio | 28.08 |
| PS Ratio | 3.387 |
| Price to Free Cash Flow | 25.48 |
| Price | 224.93 |
| Earnings Yield | 3.56% |
| Market Cap | 32.75B |
| Operating PE Ratio | 17.38 |
| Normalized PE Ratio | 20.71 |